Seres Therapeutics Inc (MCRB)

[Liquid1974]

Seeking entry.... MCRB

[Liquid1974]

I lovvvvvve blood!!!!.... Added to watch list..

[perfectpicksfor -you]

Yes its a shorty fry LOL Lets close above $ 12.00

[ClearlyStocks]

Wow. Big rebound.

[PAC]

MRCB not bad, $8 - $9.7, 20%+ bounce

[Digger 2-0]

Equities research analysts at HC Wainwright initiated coverage on shares of Seres Therapeutics Inc. (NASDAQ:MCRB) in a research report issued to clients and investors on Friday. The brokerage set a “buy” rating and a $50.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 39.78% from the company’s current price.

Seres Therapeutics (NASDAQ:MCRB) opened at 35.77 on Friday. The company’s market cap is $1.41 billion. The firm has a 50-day moving average price of $31.41 and a 200 day moving average price of $28.23. Seres Therapeutics has a 12 month low of $21.12 and a 12 month high of $52.00.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.02. The firm earned $2.71 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts expect that Seres Therapeutics will post ($1.81) earnings per share for the current year.

http://www.americanbankingnews.com/2016/07/29/seres-therapeutics-inc-mcrb-research-coverage-started-at-hc-wainwright/

[Digger 2-0]

Looks like back to 10++++ $$$

[T695]

Back to $8?

[ClearlyStocks]

Lol. Looks like $5 coming

[PAC]

Well it drop from $10 - $7.90. Let see if it ramps to $10 only to he reshorted

[PAC]

Hearing $7 cash? thinking MCRB -83%+ for tradable bounce, so $7 under

[ClearlyStocks]

Will crash. Company has no money

[apollo1452]

Why "treat" C Diff when U can Prevent???
SYN-004 will dominate the C Diff market because it's the only product that PREVENTS C Diff from occurring in the first place. SYN is incredibly undervalued at 297M mkt cap. Check out the SYN catalysts still coming in 2015:

Release of Dr Voskuhl article on Trimesta in respected science journal
Release of Trimesta MRI analysis
Partnership(s) announced for Trimesta
Phase 2a results for SYN-004
Phase 2b results for SYN-004
Phase 2 results for SYN-010
Update on development of "SYN-P2A"
Partnership for SYN-004
Partnership for SYN-010
Funding Partner for SYN-005
Announcement of XON collaboration with acinetobacter

[someconcerns]

Protag, Please forgive my ignorance, but how does the Seres pill differ (at least in concept) from taking probiotic capsules with "helpful bacteria?" I recognize that each health company's probiotics represent different mixtures of bacteria in the gut of healthy people, so each is different. But the concepts sure sound similar to this non-biologist. TIA for pointing me in the right direction.

[INTEGRITY STOCKS]

MCRB CONGRATS to her "Betty Bacon's big $50,000 win on Friday with Seres Therapeutics (MCRB)"
http://www.thelion.com/bin/forum.cgi?sf=MCRB&msg=24&cmd=r&t=

[protagonist12]

Let us know what you find out...

[BigPennyHunter]

Woserz!! Gonna have to look at what happened here and see which direction this is gonna head and how fast.

[mkinhaw]

Nice pop, for being in phase 2 only

should retrace some

MK

[protagonist12]

Seres Therapeutics, Inc. today announced the pricing of its initial public offering of 7,430,555 shares of common stock at a public offering price of $18.00 per share, before underwriting discounts and commissions. All of the common stock is being offered by Seres Therapeutics. In addition, Seres Therapeutics granted the underwriters a 30-day option to purchase up to an additional 1,114,583 shares of common stock from the company at the public offering price. The company's shares are expected to begin trading on The NASDAQ Global Select Market on June 26, 2015 under the ticker symbol "MCRB".

Goldman, Sachs & Co. and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Leerink Partners and Canaccord Genuity Inc. are acting as lead managers for the offering.

[protagonist12]

Seres Therapeutics, an upstart biotech company, filed with the SEC on May 27, 2015 for its IPO, set to price on June 26, 2015. Based in Cambridge, MA, Seres develops therapies for antibiotic-resistant infections, such as Clostridium Difficile, known as CDI.

The firm plans to offer 6,250,000 shares of common stock, with a price target of $15-17 per share. Seres plans to raise $89.8 million, or $103.7 million if the underwriters exercise in full their option to purchase additional shares. Goldman Sachs and Bank of America Merrill Lynch are the lead underwriters of the IPO, with Canaccord Genuity and Leerink Partners rounding out the syndicate.

The proceeds will be used to continue its research of the microbiome, where Seres is a pioneer in lead therapy technology. The company hopes to develop new therapies for antibiotic-resistant infections through continued research of the microbiome. The current target infection is Clostridium Difficile, known as CDI.

The company garnered attention in the biotech industry in 2014, when its lead therapy, SER-109, blocked CDI from recurring in 29 out of 30 patients. Seres plans to use approximately $25 million to advance the development of SER-109. Currently, it is in phase 2 development of the therapy, and Seres believes the funds will help complete the development. The company plans to use an additional $40 million to continue research on other product candidates similar to SER-109.

S-1 here:
http://www.nasdaq.com/markets/ipos/filing.ashx?filingid=10297871